Anti-PDGFRα antibody, olaratumab, was found to have promising results in GBM xenografts, significantly inhibiting tumour growth in vivo with a concomitant reduction in PDGFR phosphorylation [18, 19]. Here, PDGFRB is linked to neoplasm.